What is Ovagen 20MG

Ovagen 20MG is a synthetic tetrapeptide bioregulator of the Khavinson class studied in research for its targeted effects on liver function, digestion, and gastrointestinal repair. It is intended exclusively for research use.

Regarding its chemical identity, Ovagen has a molecular formula of C14H24N4O7 and a molecular weight of 360.4 g/mol. Its reported canonical sequence is Glu-Asp-Pro-Leu. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Ovagen.

Product for research use.

Mechanism of action of Ovagen

Ovagen enters the nucleus of hepatocytes and cells of the gastrointestinal tract, where it acts as an epigenetic switch. It upregulates the synthesis of enzymes responsible for detoxification and structural repair, normalizing lipid metabolism and reducing liver inflammation.

Pharmacokinetics and pharmacodynamics of Ovagen

It features an exceptionally short plasma half-life. Its mechanism does not rely on constant receptor binding; rather, a brief exposure triggers a sustained cascade of genetic transcription and protein synthesis within the liver.

Scientific evidence on Ovagen

The available evidence on Ovagen is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in preclinical models of toxic liver damage (such as carbon tetrachloride poisoning), hepatitis, and metabolic syndrome. Evidence suggests it accelerates the restoration of normal liver enzyme panels and prevents the progression of hepatic fibrosis.

Ovagen applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Ovagen protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Ovagen, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Ovagen

As a general guideline for laboratory handling, lyophilized peptides such as Ovagen are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Ovagen Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Ovagen security profile

The documented safety information in open sources for Ovagen is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Targeting epigenetic regulation specifically within the liver and GI tract, it lacks widespread systemic toxicity in animal models. However, its safety and efficacy remain strictly theoretical and unverified in formal human trials outside of Russia.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Ovagen in a comparative context

Ovagen is the synthetic counterpart to Svetinorm (a natural liver extract). Compared to Livagen (which also targets the liver but focuses heavily on immune senescence and chromatin decondensation), Ovagen is more specifically aligned with direct hepatic detoxification and gastrointestinal integrity.

History and development of Ovagen

Developed by Vladimir Khavinson as part of the Cytogen family of synthetic bioregulators. It was designed to mimic the active signaling molecules found in young, healthy animal livers to treat age-related hepatic decline and toxic exposure.